Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


11 agosto 2017

Lutonix registry data confirm durability of drug-coated balloon treatment in superficial femoral artery disease

Interventional News

The 24-month results of the worldwide experience with Lutonix 035 drug-coated balloon (CR Bard/Beckton Dickenson) were published online in August in JACC: Cardiovascular Interventions. Data revealed that patients with femoropopliteal lesions who were treated with the drug-coated balloon experienced symptom improvement and that low reintervention rates were observed at 24 months, even in patients with difficult-to-treat lesions.

31 julio 2017

Merit Medical partners with world-renown interventional cardiologist to deliver transradial course

Interventional News

Merit Medical will partner with internationally renowned interventional cardiologist Ferdinand Kiemeneij to deliver the next generation in educational opportunities for interventional cardiologists and interventional radiologists. Kiemeneij will serve as a co-proctor at the upcoming Advanced Transradial Intervention Education Course for Interventional Cardiologists (13–14 October, Merit Medical Education Cente, Salt Lake City, USA).

31 agosto 2017

Could new study showing significant blood pressure reductions reignite interest in renal denervation?

Interventional News

Medtronic has announced its intent to move forward with a new renal denervation pivotal trial following positive first results from a sham-controlled study in patients with high blood pressure. Investigators of the SPYRAL HTN-OFF MED Study found statistically significant and clinically important blood pressure reductions in the patients treated with renal denervation across both office and ambulatory systolic and diastolic measurements. The data in the first 80 patients enrolled in the study at three months were presented in a late-breaking clinical trial session at the European Society of Cardiology (ESC) meeting in Barcelona, Spain and published simultaneously in The Lancet.

29 junio 2017

Philips acquires CardioProlific

Interventional News

Royal Philips has announced the acquisition of CardioProlific Inc, a USA-based, privately-held company that is developing catheter-based thrombectomy approaches to treat peripheral vascular disease. Financial details of the transaction will not be disclosed.

11 agosto 2017

Philips completes acquisition of Spectranetics

Interventional News

Philips has announced that it has completed the acquisition of The Spectranetics Corporation, a US-based global leader in vascular intervention and lead management solutions. Spectranetics’ financial results will be consolidated as part of Philips’ Image-Guided Therapy business group as of 9 August 2017.

28 junio 2017

Philips sets sights on Spectranetics, also acquires CardioProlific

Interventional News

Royal Philips and The Spectranetics Corporation announced that they have entered into a definitive merger agreement. Pursuant to the agreement, Philips will commence a tender offer to acquire all of the issued and outstanding shares of Spectranetics for US$38.50 per share, to be paid in cash upon completion.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.